INNPF · INNOCAN PHARMA Corp
Market Cap
$7.87M
Shares
4.50M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.75
Open$1.75
Day$1.75–1.75
52W close$1.43–14.26
Avg vol 30d231
Short int15 · 0.0% float · 1.0d
Short vol50%
DataNov 2020–Sep 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−89%
below
Price vs 50-day avg
−57%
below
RSI (14)
38
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−29%
trailing
6-month return
−84%
trailing
YTD return
−76%
this year
Relative strength
−99%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $16 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
12
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
264%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
15.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−89%
Bearish
Price vs 50-day avg
−57%
Bearish
RSI (14)
38
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $4 › 200d $16 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $1
Now $2 · 2%
Range high $14
vs 200-day avg -89%
vs 50-day avg -57%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Household & Personal Products — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INNPF
this stock
INNOCAN PHARMA Corp
|
$7.87M | — | — | — | 0.0% |
|
PG
PROCTER & GAMBLE Co
|
$335.19B | +3.0% | +3.3% | 21.8 | 1.2% |
|
UL
Unilever PLC
|
$134.65B | -4.9% | — | — | 0.2% |
|
CL
Colgate Palmolive Co
|
$69.59B | +11.0% | +1.7% | 34.5 | 2.2% |
|
RBGLY
Reckitt Benckiser Group PLC
|
$43.59B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INNPF | +22.4% | -28.6% | -83.5% | +8.0% | -75.8% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +22.3% | -28.2% | -98.7% | +7.6% | -88.7% |